Alar Pharmaceuticals Inc. (TPEX:6785)
Taiwan
· Delayed Price · Currency is TWD 133.00
+2.00 (1.53%)
Apr 2, 2025, 1:30 PM CST
Alar Pharmaceuticals Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
| Revenue | 5.82 | 469.27 | 0.8 | - | 0.6 | Upgrade
|
| Revenue Growth (YoY) | -98.76% | 58559.00% | - | - | - | Upgrade
|
| Cost of Revenue | 2.03 | - | - | - | - | Upgrade
|
| Gross Profit | 3.79 | 469.27 | 0.8 | - | 0.6 | Upgrade
|
| Selling, General & Admin | 14.39 | 27.03 | 13.15 | 11.41 | 11.04 | Upgrade
|
| Research & Development | 57.34 | 56.71 | 34.18 | 81.89 | 160.33 | Upgrade
|
| Operating Expenses | 71.73 | 83.75 | 47.33 | 93.3 | 171.37 | Upgrade
|
| Operating Income | -67.94 | 385.53 | -46.53 | -93.3 | -170.77 | Upgrade
|
| Interest Expense | -0.03 | -0.06 | -0.02 | -0.02 | -0.03 | Upgrade
|
| Interest & Investment Income | 66.31 | 16.92 | 2.79 | 1.5 | 1.62 | Upgrade
|
| Earnings From Equity Investments | -8.54 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 46.72 | -11.32 | 1.67 | 0.07 | 0.1 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.53 | 0.04 | 9.55 | 27.52 | 26.28 | Upgrade
|
| EBT Excluding Unusual Items | 37.05 | 391.11 | -32.54 | -64.23 | -142.8 | Upgrade
|
| Pretax Income | 37.05 | 391.11 | -32.54 | -64.23 | -142.8 | Upgrade
|
| Income Tax Expense | 18.88 | 8.49 | -12.67 | - | - | Upgrade
|
| Net Income | 18.17 | 382.62 | -19.87 | -64.23 | -142.8 | Upgrade
|
| Net Income to Common | 18.17 | 382.62 | -19.87 | -64.23 | -142.8 | Upgrade
|
| Net Income Growth | -95.25% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 66 | 57 | 57 | 57 | 50 | Upgrade
|
| Shares Outstanding (Diluted) | 66 | 57 | 57 | 57 | 50 | Upgrade
|
| Shares Change (YoY) | 16.08% | 0.09% | - | 14.21% | 42.59% | Upgrade
|
| EPS (Basic) | 0.27 | 6.71 | -0.35 | -1.13 | -2.86 | Upgrade
|
| EPS (Diluted) | 0.27 | 6.71 | -0.35 | -1.13 | -2.86 | Upgrade
|
| EPS Growth | -95.98% | - | - | - | - | Upgrade
|
| Free Cash Flow | -69.84 | 397.23 | -34.09 | -65.05 | -142.31 | Upgrade
|
| Free Cash Flow Per Share | -1.05 | 6.96 | -0.60 | -1.14 | -2.85 | Upgrade
|
| Dividend Per Share | 0.250 | 1.500 | - | - | - | Upgrade
|
| Dividend Growth | -83.33% | - | - | - | - | Upgrade
|
| Gross Margin | 65.15% | 100.00% | 100.00% | - | 100.00% | Upgrade
|
| Operating Margin | -1168.02% | 82.15% | -5815.88% | - | -28460.83% | Upgrade
|
| Profit Margin | 312.36% | 81.53% | -2483.88% | - | -23799.50% | Upgrade
|
| Free Cash Flow Margin | -1200.58% | 84.65% | -4260.75% | - | -23717.83% | Upgrade
|
| EBITDA | -65.43 | 387.58 | -44.16 | -90.82 | -168.78 | Upgrade
|
| EBITDA Margin | - | 82.59% | - | - | - | Upgrade
|
| D&A For EBITDA | 2.51 | 2.05 | 2.36 | 2.48 | 1.99 | Upgrade
|
| EBIT | -67.94 | 385.53 | -46.53 | -93.3 | -170.77 | Upgrade
|
| EBIT Margin | - | 82.15% | - | - | - | Upgrade
|
| Effective Tax Rate | 50.96% | 2.17% | - | - | - | Upgrade
|
Updated Mar 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.